GlassScriptPhysician profile
John J Willis
NPI 1831149194
$14,686.42
in general payments reported to CMS, 2019-2025
58 companies · $883 in 2025
The $883 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,289 · 2022: $2,844 · 2023: $3,990 · 2024: $3,681 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,437 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,436.56 |
| Education | $117.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,150.07 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $829.36 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $725.59 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $694.50 | 2021-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $655.69 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Harmony Biosciences LLC | $577.17 | 2022-2024 | Wakix |
| Janssen Pharmaceuticals, INC | $561.53 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $526.21 | 2021-2024 | Trelegy Ellipta, Nucala |
| Neurocrine Biosciences, INC. | $496.44 | 2022-2025 | Ingrezza |
| Pfizer INC. | $456.54 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $455.40 | 2021-2024 | Abilify Mycite, Rexulti, Abilify Maintena |
| Lundbeck LLC | $449.13 | 2023-2024 | Abilify Asimtufii, Abilify Maintena, Vyepti |
| Idorsia Pharmaceuticals US INC | $371.64 | 2022-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $249.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.44 | 2021-2022 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $218.08 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Zynex Medical, INC. | $212.73 | 2025 | Nexwave |
| Impel Pharmaceuticals INC. | $204.91 | 2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $204.61 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Sunovion Pharmaceuticals INC. | $181.19 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $172.01 | 2024-2025 | Tlando |
| Biohaven Pharmaceuticals, INC. | $168.04 | 2021 | |
| Redhill Biopharma INC. | $153.72 | 2021-2022 | |
| Alk-Abello, INC | $128.38 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.52 | 2021-2023 | |
| Almatica Pharma LLC | $101.43 | 2023-2024 | Loreev Xr, Gralise |
| Nestle Healthcare Nutrition INC. | $94.39 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $92.89 | 2022-2024 | Ztlido |
| Exact Sciences Corporation | $89.27 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Philips North America LLC | $86.65 | 2021-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (Ck7) Extended Holter |
| Antares Pharma, INC. | $80.07 | 2024-2025 | Xyosted |
| Axsome Therapeutics, INC. | $79.15 | 2024 | Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.25 | 2022-2024 | Caplyta |
| Viiv Healthcare Company | $74.61 | 2024 | Apretude |
| Aimmune Therapeutics, INC. | $66.40 | 2024 | |
| Merck Sharp & Dohme LLC | $63.53 | 2021-2023 | Verquvo, Belsomra |
| Dexcom, INC. | $53.35 | 2024 | Dexcom G7 Gss (161) |
| Halozyme INC | $53.20 | 2023 | |
| Daiichi Sankyo INC. | $52.46 | 2024 | Injectafer |
| Grifols USA, LLC | $38.41 | 2021 | |
| Kyowa Kirin, INC. | $36.98 | 2024 | Crysvita |
| Myovant Sciences INC. | $33.11 | 2022 | |
| Abbott Laboratories | $32.57 | 2024 | Freestyle Libre 3 |
| Verona Pharma, INC. | $27.42 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $25.55 | 2023 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $25.25 | 2025 | Purified Cortrophin Gel |
| Sanofi Pasteur INC. | $24.92 | 2023 | |
| Hologic Sales and Service, LLC | $24.51 | 2025 | Aptima |
| Medtronic, INC. | $22.53 | 2021 | |
| Tandem Diabetes Care, INC. | $19.87 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $19.75 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.27 | 2024 | Nuzyra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.92 | 2022 | |
| Genentech USA, INC. | $16.80 | 2021 | |
| Sumitomo Pharma America, INC. | $16.09 | 2023 | Myfembree |
| Mayne Pharma Commercial LLC | $15.08 | 2023 | |
| Medicomp INC | $13.65 | 2021 | |
| Advanced Respiratory, INC | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.